Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...
MarketBeat on MSN
BioAge Labs R&D Day: BGE-102 phase I shows big hs-CRP drops, sets up cardio & DME POC trials
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant ...
MarketBeat on MSN
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...
Izicopan is an investigational next-generation oral C5aR1 inhibitor designed to achieve differentiated pharmacological properties, with the potential for improved efficacy and safety. The marketed ...
Patterns of molecular activity in the blood may hold clues not only to how fit someone is, but also to the biological ...
CEO Tim Young provides candid update on Austin pilot findings, manufacturing strategy, and the company’s dual-track technology roadmapCORALVILLE, ...
Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results